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High Risk of Infection During Triple Therapy with First-
Generation Protease Inhibitors: A Nationwide Cohort Study 
Floor A.C. Berden1, Inke M.J.M. van Zwietering1, Raoel Maan2, Robert J. de Knegt2, Wietske Kievit3, Joost P.H. Drenth1
INTRODUCTION
For many years pegylated 
interferon alpha (PegIFN) has 
been the backbone of chronic 
hepatitis C (CHC) treatment. 
The introduction of the first-
ge n e r at i on  d i re c t  a c t i ng 
antivirals (DAAs), telaprevir and 
boceprevir, initiated a cascade of 
developments of new generation 
DAAs [1]. From 2014 onwards, 
PegIFN-free treatment options 
with higher cure rates and 
better tolerability have become 
ORIGINAL PAPER
ABSTRACT
Background & Aims: Peginterferon (PegIFN) remains the backbone of therapy for chronic hepatitis C (CHC) 
in economically constrained regions. However, PegIFN may cause neutropenia and addition of a protease 
inhibitor can increase the likelihood of neutropenia. The aims of this study were to assess the occurrence of 
clinically relevant infections during first-generation protease inhibitor based therapy and its risk factors as 
well as the relation to treatment-induced neutropenia.
Methods: This multicenter (n=45) retrospective cohort study included CHC patients treated in the Netherlands. 
Based on absolute neutrophil count, categories of neutropenia were defined as: severe (<500/μL), moderate 
(500-750/μL) and mild (750-1500/μL). Likewise, infections were classified as severe (intravenous antibiotics/
hospitalization) and moderate (anti-infective treatment). We assessed risk factors for infections using 
multivariable regression analysis with correction for multiple measurements.
Results: We included 467 CHC patients, 319 (68%) were male and 111 (24%) had cirrhosis. A total of 185 
clinically relevant infections (34 severe) occurred in 145 patients (31%). During treatment 310 patients 
experienced neutropenia (34 severe). Multivariable analysis identified female sex (OR 1.7, 95%CI 1.2-2.5), 
chronic obstructive pulmonary disease (COPD) (OR 2.7, 95%CI 1.6- 4.5) and diabetes mellitus (OR 1.7, 
95%CI 1.0-3.0) as risk factors for infections. Neutropenia at the previous visit was not associated with infection 
(univariable analysis: OR 0.9, 95%CI 0.6-1.3).
Conclusion: This study shows that therapy with first generation protease inhibitors was complicated by an 
infection in 31% of patients. Not neutropenia, but female sex, COPD and diabetes mellitus were independent 
risk factors for infection. These patients should be monitored carefully once a PegIFN regimen is initiated.
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available in many western countries [2]. These new PegIFN-
free regimens are very costly, limiting the availability in many 
economically deprived regions worldwide, where the majority 
of the global CHC population resides [3-6]. Guidelines still 
recommend telaprevir and boceprevir for use in countries 
where new generation DAAs are not available. Therefore, triple 
therapy still maintains its therapeutic value [7, 8]. 
One of the drawbacks of triple therapy is its high rate of 
adverse events, which often can be attributed to the use of 
PegIFN. Neutropenia is frequently reported and mainly caused 
by bone marrow suppression [9, 10]. To prevent infections, 
product labels and guidelines advise dose reductions or 
even discontinuation of treatment if neutrophil count drops 
below 750/µL or 500/µL, respectively [7, 11]. However, prior 
studies in CHC patients undergoing (Peg)IFN and ribavirin 
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(RBV) therapy did not find an association between treatment-
induced neutropenia and infections, while dose reductions of 
PegIFN can reduce effectiveness [12-17]. The situation may be 
different with triple therapy, because phase III studies found 
that the inclusion of boceprevir to the CHC treatment strategy 
increased the likelihood of neutropenia compared to PegIFN 
and RBV [18, 19]. In addition, comparative studies found more 
neutropenia in boceprevir than telaprevir treated patients [20, 
21]. Real world data furthermore suggest that triple therapy 
substantially increases the risk of severe infections. However, 
the current evidence for this association is limited to CHC 
patients with cirrhosis [22-24]. Therefore, the aims of this 
study were (i) to investigate the occurrence and risk factors 
for clinically relevant infections and (ii) the relation of on-
treatment neutropenia with infections in CHC patients who 
received triple therapy with boceprevir or telaprevir.
METHODS
Population and design
This nationwide, multicenter, real world cohort study included 
patients with CHC genotype 1 infection treated with telaprevir 
or boceprevir and PegIFN and RBV in the Netherlands (2011-
2015) [unpublished data]. Patients across all fibrosis stages 
were included. We retrospectively identified patients from 
local databases, and excluded patients with a co-infection with 
human immunodeficiency virus or hepatitis B virus. Treatment 
choice between telaprevir and boceprevir was at the discretion 
of the physician and it was administered according to national 
guidelines [25]. We conducted the study in accordance with good 
clinical practice (GCP) guidelines, and the code of conduct for 
medical research (www.federa.org). Approval from participating 
centers was obtained following local regulations.
Outcomes and definitions
The primary outcome of this study was the occurrence of 
infections during treatment up to four weeks after cessation 
of treatment. Secondary outcomes were occurrence and 
severity of neutropenia, risk factors for infection, and severity 
of infection. In addition, the time until occurrence of the first 
infection after start of treatment was assessed. Infections were 
classified as severe in case of hospitalization or intravenous 
antibiotics, moderate if oral or topical anti-infective agents were 
administered and mild if no treatment was given. Moderate 
and severe infections were considered clinically relevant. 
Based on the thresholds for dose reduction and treatment 
discontinuation of PegIFN, we distinguished three categories 
of neutropenia: severe if absolute neutrophil count (ANC) was 
below 500/µL, moderate if ANC was between 500 and 750/µL 
and mild if ANC was between 750 and 1500/µL [13, 25]. We 
used Fib-4 > 3.25 to classify patients as cirrhosis, because of its 
high performance in detecting cirrhosis and high availability of 
included biomarkers in the general population [26]. History of 
decompensated liver disease was defined as a history of ascites, 
variceal bleeding or hepatic encephalopathy.
Data acquisition
We collected all details on demographics, disease 
characteristics, infectious (serious) adverse events, and 
laboratory values. Laboratory values included hematological 
tests, creatinine, aminotransferases, and indicators of liver 
function. If two infections occurred within the same timeframe, 
we only included the most severe infection.
Statistical analysis
We described categorical variables as proportions and 
continuous variables as means (standard deviation, SD) or 
medians (interquartile range, IQR). The Kaplan-Meier method 
was used to assess time till occurrence of the first infection and 
the cumulative incidence rates of infections at 12 and 24 weeks 
after treatment initiation. Those time points were chosen as the 
introduction of new generation DAAs allows shortened use of 
PegIFN for 12 or 24 weeks [7]. Chi-square tests were performed 
to compare occurrence of at least one clinically relevant 
infection between subgroups of patients with and without 
diabetes mellitus (DM), chronic obstructive pulmonary disease 
(COPD) and cirrhosis. To identify predictors for clinically 
relevant infections we performed univariable and multivariable 
logistic regression analyses with correction for multiple 
measurements within a patient. Variables with a p-value 
≤0.2 in univariable analysis were included in multivariable 
analysis together with age, sex, cirrhosis and DM as fixed 
factors (backward stepwise method, complete cases). ANC at 
the visit prior to the occurrence of infection was included in 
univariable analysis. Odds ratios (OR) with 95% confidence 
intervals (95%CI) are reported. As a sensitivity analysis, all 
reported infections were included. 
All analyses included the intention to treat population, and 
all tests were two-sided with a significance level of p < 0.05. 
The analyses were performed using SPSS (IBM SPSS Statistics 
20) and SAS 9.3 (SAS Institute, Cary, NC, USA). 
RESULTS
Population
Our cohort study included 489 patients in total, of which 22 
were excluded. Therefore, 467 patients from 45 centers in the 
Netherlands were analyzed (Supplementary figure 1). Patients 
were treated with telaprevir (n= 265) or boceprevir (n= 202) 
and PegIFN and RBV. Mean age was 51 years (range 19-77), 
319 (68%) patients were male, and 111 (24%) patients presented 
with cirrhosis. Baseline characteristics are shown in Table I. 
Infections 
In total, 233 infections in 171 patients were reported (34 
severe, 151 moderate, and 47 mild), and thus 185 were clinically 
relevant occurring in 145 patients (31%). A total of 79 of 265 
telaprevir treated patients experienced 103 infections and 66 
of 202 boceprevir treated patients experienced 82 infections. 
Incidence and severity of infections were similar for telaprevir 
vs. boceprevir (p=0.35, Fig. 1). Main sites of infection were 
dermatological, respiratory, and gastro-intestinal (Table II). 
In total, 34 severe infections were observed in 31 patients 
(21 telaprevir and 10 boceprevir treated patients). Sites and 
diagnoses of severe infections are listed in Table III. Among 
patients with DM, COPD or cirrhosis, more infections were 
reported than in patients without DM, COPD or cirrhosis 
(DM: 46% vs. 29%, p=0.012; COPD: 57% vs. 29%, p<0.001; 
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cirrhosis 40% vs. 28%, p=0.024; Fig. 2). Infection resulted in 
death in two patients: one patient was admitted with anemia 
and sepsis (bloodculture: Klebsiella and Staphylococcus Aureus) 
and died in hospital while the other patient died from a 
mycotic endocarditis (bloodculture: Candida Parapsilosis). 
The median time to develop a clinically relevant infection 
was 14 weeks (IQR 6-26 weeks). Cumulative incidence of 
infection within first 12 weeks was 17.4% (95%CI 12.9-21.9) for 
telaprevir treatment and 12.6% (95%CI 7.9-17.3) for boceprevir 
treatment (Fig. 3). Overall, no significant differences were seen 
in the cumulative incidence of infections between telaprevir 
and boceprevir (p=0.712). 
Neutrophil counts and infections
At baseline, mean ANC was 3454/µL (SD 1532) and 21 (of 
284 available measurements) patients had severe neutropenia. 
Only 5 (24%) of these patients developed an infection (1 
severe). Neutrophil count dropped by an average of 2201/
µL (SD 1339) during treatment. A total of 310 (74%) of 419 
patients with available ANC measurements (48 patients had 
Table I. Baseline characteristics of the patients
Characteristic Overall (n= 467) No infection (n =322) Infection (n =145)
Age, years – mean (range)  51 (19-77) 50 (19-77) 52 (25-74)
Male sex – n (%) 319 (68) 234 (73) 85 (59)
White race – n (%)a 321 (89) 225 (89) 96 (91)
HCV genotype – n (%) 
     Genotype 1 indeterminate 86 (18) 64 (20) 22 (15)
     Genotype 1a 226 (48) 158 (49) 68 (47)
     Genotype 1b    155 (33) 100 (31) 55 (37)
Treatment naiveb - n (%) 273 (60) 190 (61) 83 (58)
Fib 4 index – median (IQR) 1.8 (1.1-3.3) 1.6 (1.1-2.9) 2.1 (1.3-4.1)
Fib 4 > 3.25 – n (%)c 111 (25) 67 (22) 44 (32)
History of decompensated liver disease – n (%) 24 (5) 9 (3) 15 (10)
Diabetes mellitus n (%) 54 (12) 30 (9) 24 (17)
Chronic obstructive pulmonary disease - n (%) 37 (8) 16 (5) 21 (14)
Telaprevir vs. boceprevir 265 vs. 202 186 vs. 136 79 vs. 66 
Laboratory valuesd
Hemoglobin g/dL - mean (SD) 9.1 (0.9) 9.2 (0.9) 9.0 (0.9)
Leucocyte count per μL - mean (SD) 6727 (2154) 6827 (2152) 6500 (2151)
Neutrophil count per μL - mean (SD) 3454 (1532) 3467 (1503) 3423 (1606)
Platelet count x109/L – mean (SD) 192 (76) 198 (78) 179 (71)
Albumin g/L – mean (SD) 41.4 (4.9) 41.8 (4.6) 40.7 (5.5)
Total bilirubin g/dL – median (IQR) 10.0 (7-14) 10 (7-14) 10 (7-16)
a Race: available in 360 patients (252 without infection, 108 with infection); b Previous response: available in 454 
patients (310 without infection, 144 with infection); c Fib-4 index: available in 438 patients (301 without infection, 137 
with infection); d Lab values >10% missing at baseline: neutrophil count, albumin
Fig. 1. Severity of infection in telaprevir and boceprevir-treated 
patients. The bars represent the percentage of patients who 
experienced a clinically relevant infection. A total of 79 patients treated 
with telaprevir and 66 patients treated with boceprevir experienced 
an infection.
Table II. Categories of clinically relevant infections (moderate and severe)
Site of infection Total 
infections
Moderate 
infection
Severe 
infection
Dermatological 45 40 5
Respiratory 43 29 14
Gastro-intestinal 
(incl. oral infections)
38 36 2
Renal – Urinary tract 24 22 2
Ear Nose Throat 10 10 0
General 9 4 5
Ophtalmology 5 4 1
Other* 11 6 5
Total 185 151 34
* Other includes: reproductive system (3), musculoskeletal (3), hepatobiliary 
(2), cardiac or circulatory (2), neutropenic, fever
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no ANC tests available) experienced neutropenia during 
treatment. There were more neutropenia episodes in patients 
treated with boceprevir than with telaprevir (83% vs. 67%, 
p<0.001), and we detected a trend towards a higher cumulative 
incidence of severe neutropenia among patients treated 
with boceprevir (p=0.052, Fig. 4). The median time to nadir 
neutrophil count per patient was 16 weeks (IQR 8-24 weeks), 
this was similar for both DAAs. 
In 127 of 185 (69%) clinically relevant infections, neutrophil 
count from the previous visit had been recorded and median 
neutrophil count prior to infection was 1600/µL (IQR 1.1-2.3). 
Fig. 2.  Clinically relevant infections among patients with known risk factors. The bars represent the percentage of patients who experienced a 
clinically relevant infection: 2a) patients with and without diabetes mellitus (DM); 2b) patients with and without chronic obstructive pulmonary 
disease (COPD); 2c) patients with and without cirrhosis.
Table III. Sites and diagnoses of severe infections
Site of infection No of infections Diagnoses
Respiratory 14 Pneumonia (6), pneumonia and exacerbation of chronic obstructive pulmonary disease (4), 
respiratory tract infection (3), viral pleuritis
General 5 Sepsis, febris e causa ignota (3), fever after transfusion of packed cells
Dermatological 5 Abcess, cellulitis, erysipelas, impetigo bacteremia, wound infection after sigmoid resection
Renal – urinary tract 2 Complicated urinary tract infection, urosepsis
Gastro-intestinal 
(incl. oral infections)
2 Tooth abscess, gastro-enteritis 
Ophtalmology 1 Bacterial eye infection
Other 5 Spontaneous bacterial peritonitis (SBP), neutropenic fever, endocarditis, staphylococcal 
sepsis after phlebitis, osteomyelitis
Fig. 3. Kaplan-Meier curves showing the occurrence of the first 
clinically relevant infection during treatment in patients treated with 
either telaprevir or boceprevir (12-weeks and 24-weeks cumulative 
incidence rates).
Fig. 4. Kaplan-Meier curves showing the development of severe 
neutropenia during treatment in patients treated with either telaprevir 
or boceprevir (12-weeks and 24-weeks cumulative incidence rates). 
Overall, 57 times a clinically relevant infection was diagnosed 
(moderate n=50; severe n=7) in patients who had neutropenia 
at the preceding visit (89% mild). By contrast, 1456 visits with 
neutropenia (96%) were not followed by an infection. 
Risk factors for infection 
Results of univariable and multivariable logistic regression 
analysis are shown in Table IV. Neutropenia at the previous visit 
was not associated with occurrence of infections (univariable 
OR 0.85, 95%CI 0.57-1.27). Furthermore moderate or severe 
neutropenia (ANC <750/µL) seemed to be predictive for 
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infections (OR 0.45, 95%CI 0.20-0.99), however this was not 
significant in the multivariable model. The final multivariable 
analysis identified female gender (OR 1.7, 95%CI 1.2-2.5), 
COPD (OR 2.7, 95%CI 1.6-4.5) and presence of DM (OR1.7, 
95%CI 1.0-3.0) as risk factors for infections. The presence 
of cirrhosis did not reach significance (OR 1.4, 95%CI 0.9-
2.1). When adding mild infections to the regression analysis, 
COPD and female gender remained risk factors, while DM 
lost significance (p= 0.11).
DISCUSSION
Our study demonstrates that a 24-48-week course with 
boceprevir or telaprevir, PegIFN and RBV for CHC is associated 
with a high incidence (31%) of clinically relevant infections. 
Within the first 12 weeks, the cumulative incidence of infections 
was 13-17% depending on the type of PI. Skin and respiratory 
infections were the most commonly seen. The infection 
incidence rates resemble the rates of 12-26% which are reported 
in the literature for PegIFN based therapy with and without a PI, 
indicating the magnitude of this problem [12-14, 22-24, 27-29]. 
The CUPIC cohort was the first cohort that signaled the high 
risk for severe infection with first-generation PIs in cirrhotic 
patients, and identified two important risk factors: baseline 
albumin below 35 g/L and baseline platelet count ≤ 100 x109/L 
[23]. Out of the cirrhotic patients in our cohort (n=111), 12 
patients had both risk factors, and 5 (42%) developed a severe 
infection, comparable to the CUPIC cohort (51.4%). Presence of 
only one risk factor led to a severe infection in 22% (albumin < 
35 g/L) and 8% (platelets ≤ 100 x109/L) of patients with cirrhosis, 
again resembling CUPIC data [23]. Still, the combined risk 
factors were not identified as predictor for clinically relevant 
infections here. The independent factors that drove the risk 
for infection in our study were female sex, DM and COPD, but 
not neutropenia. The association of female sex with infections 
during CHC therapy has been reported previously and was 
explained by a higher incidence of urinary tract infections (UTI) 
or vaginal infections [13, 27]. Our findings are in agreement with 
these studies as 14% of clinically relevant infections were UTIs 
or vaginal infections (n=26) and 92% of these were observed 
in females. Another explanation might be the higher incidence 
of cirrhosis in females compared to males in our cohort (54% 
vs. 22%). Cirrhosis is established as a risk factor for infection 
in the literature, whilst our cohort only showed a trend for 
significance in the multivariable analysis [30-32]. The higher 
proportion of females with cirrhosis in our cohort might have 
influenced the regression analysis. Diabetes mellitus is a known 
risk factor for infection, but it  is also associated with CHC [33]. 
A higher infection rate in diabetic CHC patients was therefore 
hypothesized and could be explained by various factors, such as 
vascular insufficiency and impaired leucocyte function in these 
patients [12, 13, 34, 35]. Our study implies that diabetic patients 
should be monitored for infection during CHC therapy. The only 
other triple therapy cohort study that assessed risk of infection 
was restricted to cirrhotics and found that respiratory infections 
were overrepresented in those on PI therapy [22]. Our cohort 
supports this finding, as respiratory infections accounted for 
41% of severe infections and 19% of moderate infections. The 
identified risk factor COPD might relate to this, as COPD is a 
known risk factor for respiratory infections [36]. 
The risk factors in our study (female sex, DM and COPD) 
are factors that cannot be influenced and are not related to 
Table IV. Logistic regression analysis with correction for multiple measurements within a patient.
Variable Univariable OR (95% CI) p-value Multivariable OR (95% CI) p-value
Age 1.019 (0.997-1.042) 0.091
Female sex 1.728 (1.243-2.401) 0.001 1.722 (1.169-2.534) 0.006
Body mass index 0.997 (0.933-1.064) 0.917
Cirrhosis 1.767 (1.135-2.751) 0.012 1.398 (0.921-2.122) 0.116
Treatment experienced 1.136 (0.758-1.702) 0.537
Telaprevir vs. boceprevir 1.144 (0.766-1.708) 0.510
History of decompensated liver disease 1.850 (0.838-4.082) 0.128
Diabetes mellitus 1.737 (0.959-3.146) 0.069 1.734 (1.008-2.983) 0.047
Chronic obstructive pulmonary disease 3.117 (1.811-5.366) <0.001 2.701 (1.635-4.463) <0.001
Use of corticosteroids at baseline 2.312 (1.081-4.946) 0.031
Leucocyte count per μL 0.995 (0.903-1.096) 0.917
Neutrophil count per μL 1.066 (0.938-1.211) 0.329
Absolute neutrophil count < 1500 per μL 0.850 (0.570-1.266) 0.423
Absolute neutrophil count < 750 per μL 0.448 (0.203-0.989) 0.047
Baseline albumin, g/L 0.973 (0.925-1.024) 0.293
Albumin < 35 g/L 1.608 (0.820-3.151) 0.167
Platelet count, x109/L 0.996 (0.993-0.999) 0.007
Platelet count < 100 x109/L 1.619 (0.837-3.131) 0.152
Albumin < 35 g/L and platelet count < 100 x109/L) 3.091 (0.974-9.813) 0.056
Bilirubin, g/dL 1.001 (0.999-1.002) 0.388
OR=Odds Ratio; 95% CI= 95% Confidence Interval
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the type of CHC therapy. They are furthermore identified by 
previous CHC cohorts with (Peg)IFN and RBV regimes [12, 
13, 36, 37]. It is therefore likely that they remain risk factors for 
infection in future IFN-containing CHC regimes, thus these 
patients should be monitored carefully for infection during 
any PegIFN based regime.
Drug induced neutropenia is thought to be an important 
risk factor for infection. This stems from oncologic research as 
development of neutropenia following chemotherapy usually 
heralds a severe clinical situation necessitating admission and 
prompt administration of antibiotics [38]. There is a wealth of 
literature that establishes that PegIFN induced neutropenia 
does not pose an increased risk for infections in CHC patients 
[12, 22, 39]. Indeed, in our cohort neutropenia did not increase 
the risk of infection; it even seemed to be associated with a lower 
risk for infections. Altogether this suggests that neutropenia 
due to chemotherapy is different from that due to PegIFN. 
Oncology patients differ in factors which affect susceptibility 
for infection such as alteration of organ function caused by 
their underlying disease and presence of mucosal damage [40, 
41]. Because these findings are absent in stable CHC patients, 
it is reasonable to believe that CHC patients receiving triple 
therapy are less immune-compromised than oncology patients 
and that thresholds for PegIFN dose reductions, based on the 
presence of neutropenia, may be too strict. 
The advent of new generation DAAs allows to pinpoint 
the culprit for neutropenia in CHC. Neutropenia still occurs 
with any PegIFN containing regimen regardless of the DAA 
included [42-45]. IFN-free regimens do not cause neutropenia 
suggesting that PegIFN is the cause rather than CHC, DAA 
or RBV [43]. Here, boceprevir was associated with higher 
neutropenia rates than telaprevir. Whether this PI interacts 
with PegIFN for inducing neutropenia or whether it is a 
class effect of the PIs, cannot be assessed in this study. This 
finding should be interpreted with caution. Despite the higher 
incidence of neutropenia, infection rate was comparable 
between both drugs, confirming the lack of association between 
neutropenia and infections in CHC therapy.
The strengths of this study are both the size of our real 
world cohort and its nationwide character. Unique to our 
cohort is that it includes CHC patients across all fibrosis 
stages in the Netherlands and is not limited to cirrhotic 
patients. Patients visited the clinic frequently resulting in 
detailed records. However, the retrospective design enhances 
the risk of reporting bias. We made an effort to minimize this 
risk by adhering to a strict definition of severity of infections 
and restricting our analysis to infections necessitating anti-
infective therapy. Furthermore, telaprevir and boceprevir 
are first generation DAAs that have lost market share in 
view of the advent of more effective and better tolerable new 
generation DAAs. However, these drugs continue to be used in 
economically deprived countries that use PegIFN as a backbone 
for CHC therapy [46, 47]. 
CONCLUSION
Our real world nationwide cohort study showed that the 
incidence of infections during PegIFN-based triple therapy 
is high, even among patients without cirrhosis. Neutropenia 
occurs frequently, but does not increase the risk for infection. 
Female gender, DM and COPD, however, are risk factors 
for infection and are independent of type of CHC therapy, 
suggesting that these patients should be carefully monitored 
for infections once a PegIFN-based regimen is initiated. 
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Nationwide 47 hepatitis treatment centers 
Exclusion of centers: 
- 1 center: no treated patients  
- 1 centre: tardily assessment 
of study protocol 
Data collection in 45 centers (8 academic)  
 
489 patients identified 
22 patients excluded  
- 5 no consent 
- 6 treatment not finished at time of 
data collection 
- 4 treatment in another centre 
- 3 missing files 
- 2 peginterferon/ribavirin instead 
of triple therapy 
- 2 HBV co-infected 
467 patients received at least one dose of 
telaprevir (n= 265) or boceprevir (n=202) 
